Payment overview · 2025
General Payments
$100,198.83
105 reported records · 6 companies
Healthcare provider profile · identity verified
Osama Amro, MD., MS
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · SEATTLE, WA · NPI 1154642643
Verified facts
What the public records show
CMS Open Payments records show Osama Amro, MD., MS received $100,198.83 in general payments during 2025 across 105 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 54.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Filspari, Jynarque, Kerendia.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Kerendia by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JYNARQUE as an associated drug or biological on 11133 records involving 4164 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jynarque by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JYNARQUE as an associated drug or biological on 38 records involving 37 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jynarque by this doctor in 2024.
Travere Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Filspari as an associated drug or biological on 8542 records involving 2693 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Filspari by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $54,739.97 | 54.6% | 53 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $24,861.56 | 24.8% | 18 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $12,483.11 | 12.5% | 22 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $7,891.25 | 7.9% | 9 | 2025 |
| Vantive US Healthcare LLC | Unresolved — no canonical attribution shown | $122.37 | 0.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $100.57 | 0.1% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $50,557.50 | 16 |
| Consulting Fee | $33,467.00 | 10 |
| Travel and Lodging | $8,433.21 | 39 |
| Compensation for serving as faculty or as a speaker for a medical education program | $5,400.00 | 3 |
| Food and Beverage | $2,341.12 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $25,140.39 | 25 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $13,927.23 | 7 | 2025 |
Source payment records
|
|||||
| VOYXACT Normalized: voyxact |
Drug | Otsuka America Pharmaceutical, Inc. | $6,658.60 | 10 | 2025 |
Source payment records
|
|||||
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $827.32 | 6 | 2025 |
Source payment records
|
|||||
| Renal - PD Normalized: renal pd |
Device | Vantive US Healthcare LLC | $122.37 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $100.57 | 2 | 2025 |
Source payment records
|
|||||
| Vanrafia Normalized: vanrafia |
Drug | Novartis Pharmaceuticals Corporation | $38.07 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Filspari filspari |
2025 | Filspari | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JYNARQUE jynarque |
2025 | Jynarque | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | JYNARQUE open payments reported associated product |
CMS Open Payments — General Payments 11133 supporting records · 4164 recipient NPIs · example record 1227267725 |
Jynarque · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | JYNARQUE open payments reported associated product |
CMS Open Payments — General Payments 38 supporting records · 37 recipient NPIs · example record 1225320011 |
Jynarque · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Travere Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Filspari open payments reported associated product |
CMS Open Payments — General Payments 8542 supporting records · 2693 recipient NPIs · example record 1244395624 |
Filspari · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Calcitriol | Calcitriol | 282 | 70 |
| Furosemide | Furosemide | 257 | 85 |
| Farxiga | Dapagliflozin Propanediol | 229 | 55 |
| Losartan Potassium | Losartan Potassium | 219 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 217 | 74 |
| Hydralazine Hcl | Hydralazine Hcl | 118 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 36 |
| Carvedilol | Carvedilol | 100 | 24 |
| Allopurinol | Allopurinol | 69 | 22 |
| Lisinopril | Lisinopril | 66 | 18 |
| Spironolactone | Spironolactone | 66 | 21 |
| Kerendia | Finerenone | 61 | 15 |
| Jardiance | Empagliflozin | 56 | 19 |
| Calcium Acetate | Calcium Acetate | 52 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 51 | 17 |
| Prednisone | Prednisone | 51 | 21 |
| Sevelamer Carbonate | Sevelamer Carbonate | 43 | 17 |
| Omeprazole | Omeprazole | 39 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 38 | 15 |
| Jynarque | Tolvaptan | 37 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 36 | 14 |
| Potassium Citrate Er | Potassium Citrate | 35 | 11 |
| Gabapentin | Gabapentin | 33 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 29 | 11 |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Filspari | Sparsentan | 24 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 23 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 21 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 20 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Eplerenone | Eplerenone | 14 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 14 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $100,198.83 · 105 records | Otsuka America Pharmaceutical, Inc. | Fabhalta, Filspari, JYNARQUE, Kerendia, Renal - PD, VOYXACT, Vanrafia | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Filspari play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error